🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX ¡ Real-Time Price ¡ USD
9.38
-0.22 (-2.29%)
At close: Nov 18, 2026, 4:00 PM EST
9.24
-0.14 (-1.49%)
Pre-market: Nov 19, 2026, 4:01 AM EST
← View all transcripts

Stifel 2026 Healthcare Conference 2026

Nov 11, 2026

Summary

Ficerafusp alfa’s pivotal head and neck study is expected to report top-line data in mid-2027, with an OS interim analysis planned. FORTIFI-FLEX tests less-frequent maintenance dosing, while CRC data are due at ASCO GI in January.

Stephen Willey
Senior Biotech Analyst, Stifel

All right. We are going to go ahead and get started. I am Stephen Willey, one of the Senior Biotech Analysts here at Stifel. Glad to have with us Ryan Cohlhepp, who is the CEO of Bicara Therapeutics. We are just going to have a casual discussion. If anyone has a question, feel free to raise your hand, and we will get you acknowledged and your question answered. Ryan, thanks for being here. Anything you want to say from an opening statement perspective before we jump into Q&A?

Ryan Cohlhepp
CEO, Bicara Therapeutics

Yeah, sure. Maybe just, I think, step back and ground, for those who may not be as familiar with the Bicara story, is our lead program that we have been developing over the last several years is ficerafusp alfa. It is an EGFR/TGF-β trap that we are developing in a pivotal study in recurrent metastatic head and neck cancer. As we go back to even the design of that molecule and what we were looking to accomplish is TGF-β, for almost 40 years now, has been considered a target that should work. I think there have been many in oncology, TGF-β is one of them. I think there were some notable failures, one of which Merck KGaA had bintrafusp alfa, which was a PD-L1 TGF-β. When we were designing the molecule, we thought that the shortcoming with TGF-β was getting adequate levels of it to the tumor.

Thought if we are able to localize and direct it to the tumor, we could see activity that ultimately fulfill the promise of TGF-β and the biology, the underlying biology. I think we have absolutely been able to do that. What we have demonstrated in the head and neck population, the ability to just to almost triple response rates. We have got mature follow-up in our phase I cohorts now out to beyond three years, where we are showing a median overall survival in an HPV-negative population of close to 22 months, which is 10 months greater than what you see with the standard of care right now. At the three-year mark, we have been able to demonstrate that we have twice as many patients alive at the three-year mark that would have been alive otherwise with KEYTRUDA.

I think that was all, that data was the basis for investing in and initiating the pivotal trial, the FORTIFI-HN01 trial, which we are anticipating data, top line, middle of next year, which we are really excited about. Again, based on the data that we have seen for ourselves and the class in general, do believe that we have a profile based on the depth and durability that TGF-β delivers, that will allow us to show meaningful and a best-in-class overall survival profile.

Stephen Willey
Senior Biotech Analyst, Stifel

Okay, great. I generally don't like to start off talking about other people's drugs during these things.

Ryan Cohlhepp
CEO, Bicara Therapeutics

Let's do it.

Stephen Willey
Senior Biotech Analyst, Stifel

Let's do it. Just given that seems like a very appropriate place to start here, given the Genmab disclosure from a couple weeks ago. How are you and, I guess, your team just interpreting kind of the headline response rate and OS statistics that were provided in the phase III frontline trial press release? We'll have some follow-ups from there.

Ryan Cohlhepp
CEO, Bicara Therapeutics

Yeah. With that release, again, I think there was a fairly limited data that Genmab put out there. As we've evaluated that, both in terms of what we believe that data tells us from a differentiation perspective and how we ultimately will stack up against the petosemtamab molecule. But also, probably even more importantly, is what can we read through as we think about our own study, what we want to do, how we're executing, and how we're operationalizing the FORTIFI-HN01 study. At the end of the day, we can only control what we can control, and the conduct of the FORTIFI trial is one of those things. As we look at that, the two key pieces of data were on response rate. They chose to present the data based on an odds ratio, so you have to make some assumptions based on the control arm.

What we did hear from Genmab is that it was consistent with what you've seen historically with pembro as a control arm in these types of trials. I think the range that we would model there would be somewhere between 19% and 25% on a response rate basis. What that tells us is it's likely that in a blended population, and again, that's a key difference between our trial and the Genmab trial, is based upon historical data, we made the strategic decision to develop an HPV-negative population alone. We felt that both the data from our own trial as well as the historical data that was prospectively evaluated across multiple trials with EGFR monoclonal antibodies suggests that these molecules aren't going to work as well on HPV-positive patients. We chose to develop it in the population where we expect the most profound benefit.

When you look at, in that pooled population, we fully anticipate the inclusion of the HPV-positive will cause some level of deterioration in the response rate data. But what that data tells us is that even in an HPV-negative population where you're trying to compare apples to apples, you probably have seen in that trial petosemtamab delivering data consistent with what they had seen previously, probably in the mid-50s, maybe into the low 60% range on a response rate perspective. I think again, one of the scenarios that could have played out was they put up a big number in the 70s for HPV-negative. Again, we think that that scenario is very unlikely based on the data that we saw.

As you move to overall survival, which I think that's where the market has shifted to and their focus around how are these drugs ultimately going to differentiate in survival. What we saw is a hazard ratio of 0.5, but not much beyond that. The confidence intervals that they showed would suggest that it was a fairly early analysis with about 175 death events in a total trial of 700 patients. But we don't know how many of those death events were in HPV-positive patients versus HPV-negative patients, which we know will have a significant influence ultimately in what that looks like. You also think about where, if you look at the KEYNOTE-048 trial, which was a study that Merck had to support the approval of pembro in this population, the Kaplan-Meier shows a pretty aggressive decline in the first 30%- 40% of patients.

Our view, based on the number of events that are in the current analysis, is you're probably on the front end of the curve. As you think about these agents, particularly IO-based therapies, TGF-β in particular, as you think about where is that contribution going to come from, I think you start to see in the later phases of the curve. I would say even as you think about where HPV-positive patients are likely to sit in that curve, we know that HPV-positive patients live longer.

We do think that there's a high probability that that hazard ratio will deteriorate over time, which I think as you play that forward from a regulatory path perspective, I think the jury is still out in terms of ultimately what the initial approval or label will look like for petosemtamab. That being said, as we read that through to our own trial, we've got greater confidence in an ability to see a statistically significant benefit with a smaller sample size. As we think about the allocation of alpha and where you spend it, one of the things at earnings this week we communicated is we committed to an interim analysis for overall survival.

I think we've got additional data to inform the way we think about that, which, I'd much rather have that data now, when we still have runway on these decisions, versus seeing it on the other side of a top line where I think we came out of that with more information for us to inform our own strategy.

Stephen Willey
Senior Biotech Analyst, Stifel

Maybe you can talk a little bit about the interim analysis that you're now committed to conducting on survival and just, I think a lot of the questions that we get now is, okay, how is this going to align with the response rate interim analysis that I think you've pre-specified based upon a 350 or so patient fraction? You do have, as you said, exclusively HPV-negative patients in this trial. Presumably, historical outcomes would suggest that you're going to accrue death events faster. Do you think that there's an opportunity whereby you can get to that event trigger number that informs an interim by time of the response rate look?

Ryan Cohlhepp
CEO, Bicara Therapeutics

Yeah, I think it's absolutely a viable scenario. Again, what we did not, I think, pin ourselves down to on Monday was when we're going to do that interim analysis for overall survival. There's additional data that we're going to see both in our own trial, one that we continue to evaluate the rate at which we are accruing death events in the trial, in a blinded, aggregated way. So we can run scenarios off of that. Seeing continued maturity of that, I think will help inform ultimately where we think that analysis will land. We also expect that we may see data from Genmab that would give us a better view on what that curve looks like for them.

The one thing, the key guiding principle in the way we're approaching this is we continue to have a high degree of confidence in our ability to get this drug approved. The war is not going to be won on top-line data releases. It's ultimately what label we are able to put in the hands of our sales representatives and our medical team that will live with this label for a long time. We're not going to be reckless and go too early. That being said, the scenario that you painted, again, given the population in our study, we do expect to be able to accrue those death events at a rate faster than what the petosemtamab trial did.

Stephen Willey
Senior Biotech Analyst, Stifel

Okay.

Ryan Cohlhepp
CEO, Bicara Therapeutics

I think there are various scenarios on the table, and we certainly will communicate as appropriate. One of the things that I think ourselves and Genmab can definitely agree on is this is a highly competitive space. In terms of what we disclose when, we obviously know that there are many stakeholders here, including the investor community. I think we'll make that disclosure and communicate that when it's fitting.

Stephen Willey
Senior Biotech Analyst, Stifel

Okay. Yeah, I think your point around concentrating the benefit of what they're seeing from a survival perspective into that front end of the Kaplan-Meier curve is a really important one.

Ryan Cohlhepp
CEO, Bicara Therapeutics

Yeah.

Stephen Willey
Senior Biotech Analyst, Stifel

It kind of aligns with this notion of, okay, they upsized the study by 200 patients, but then didn't change the underlying statistical protocol, which meant that they were able to accelerate the number of events that occurred in that top half.

Ryan Cohlhepp
CEO, Bicara Therapeutics

Yeah.

Stephen Willey
Senior Biotech Analyst, Stifel

Right? We know that if you target EGFR, if you debulk, you are going to have an advantage over pembro in that top half. We saw that with cetuximab and chemo in KEYNOTE, right?

Ryan Cohlhepp
CEO, Bicara Therapeutics

Yeah.

Stephen Willey
Senior Biotech Analyst, Stifel

I guess in that sense, where you have an IO comparator, right, it gets really hard to compete on the tails of those curves, and that presumably feeds into your deterioration hypothesis. I guess, do you think that having TGF-β on board allows you to be more competitive on those tails?

Ryan Cohlhepp
CEO, Bicara Therapeutics

Absolutely. I would say the data that we have demonstrated out of our phase I cohort is supportive of that. You look at the three-year landmark where twice as many patients are alive compared to pembro. Again, you have got the pembro IO tail there, where we know that those patients who respond on pembro generally do pretty well. Their duration of response is out to around 24 months. One of the questions as we came into the trial was, we knew we were going to be able to increase response rates, but what was the durability of those additional responders going to look like? Again, you go back to the KEYNOTE-048 trial where you added chemotherapy and you were able to add 17% response rate, but you did not really see anything on a DOR. In fact, DOR declined dramatically.

You saw a little bit of an uptick in PFS and only less than a month improvement in overall survival. The fact that we have been able to see, we expand the responder population by almost 3X and still deliver IO-like durability absolutely speaks to where the tail effect that we are likely to see as you compare the ultimate medians from an overall survival perspective between the drugs.

Stephen Willey
Senior Biotech Analyst, Stifel

Okay. The depth and durability of response of petosemtamab really seems to be the defining characteristics of that molecule. When you talk to KOLs, how do those two things inform clinical decision-making?

Ryan Cohlhepp
CEO, Bicara Therapeutics

Yeah. I think, we can separate the depth and durability. I mean, the depth, even from a symptomatic improvement perspective, both the rapidity of response that we are seeing, we are hearing anecdotes from physicians where within two to three weeks, patients who had airway obstructions, who were not able to eat, had to eat through feeding tubes, were seeing significant reductions in tumor that allowed them to remove the traches and for them to resume normal eating. From a durability perspective, I think the key, and this has been informed by trials like the LEAP-010 trial where durability was really low, or even the addition of chemotherapy where durability dropped down by two-thirds when you added chemotherapy, is physicians know in order to see these long-term outcomes, they need to keep patients on therapy.

The durability of response is critical and a read-through ultimately to longer-term outcomes for overall survival. As we show our profile, and we have also at ASCO last year, one of the things that we were able to show is in those patients who have a reduction of their tumor of 80% or greater, what do their outcomes look like? We were able to demonstrate that you see outsized benefits in DOR, PFS, and with over three years of follow-up, we still have not met the median overall survival in those patients who had a tumor reduction of 80% or greater. As a reminder, that is not just a couple patients. We had 15 responders in our phase I dataset. 12 of the 15 had a reduction of 80% or greater.

The vast majority of our responders are those deep responders, and you are seeing outsized benefits in overall survival.

Stephen Willey
Senior Biotech Analyst, Stifel

Okay. I guess we could sit here and probably statistically speculate for the next hour like we did this morning, but let's just try to keep this moving. How are you thinking then about just kind of the size of the HPV-negative market in the U.S. and kind of the revenue opportunity that you see that's up for grabs here?

Ryan Cohlhepp
CEO, Bicara Therapeutics

Yeah. As we model and look at the epidemiology in the U.S., HPV-negative with a CPS of greater than one, so the population that sits within the potential label for the drug, about 18,000 patients. You think about the ability to it's a sizable population. You now, with a drug like Ficera, you're going to be able to significantly enhance the responder population, and you're able to significantly increase across that population their duration of therapy. Even Merck has publicly disclosed in the past that for KEYTRUDA, the head and neck population accounts for somewhere between 5% and 10% of global KEYTRUDA sales. You think about that where only one in five patients are responding to a KEYTRUDA-based therapy with a relatively short duration, depending on whether it's with chemo or not. The ability to grow that market based on greater durations, more responders.

We look at this market by 2030, and I think easily anticipate that you're going to have a $5 billion EGFR market in the recurrent metastatic head and neck population in pretty short order. I think what we consistently hear from KOLs is that upon approval, they see this class being used in the vast majority of their frontline patients.

Stephen Willey
Senior Biotech Analyst, Stifel

Okay. Maybe you could talk a little bit about the FORTIFI-FLEX trial, which you're running in parallel. This is intended to move patients to a less frequent, once every three-week dose after induction. Maybe you can just kind of talk about the trial, what you're hoping to achieve here, and how some of the dose-ranging data you've generated to- date strengthens your confidence in this induction maintenance strategy that you're proposing.

Ryan Cohlhepp
CEO, Bicara Therapeutics

Yeah. We chose an approach where we are initiating with 12 weeks of weekly therapy before we transition to every three weeks. The reason we are doing that is the efficacy profile that we have demonstrated with weekly therapy is a really high bar. We did not want to do anything that would potentially deteriorate from the speed of response, the depth of response, and ultimately the durability. What we know in our data from 1,500 mg is by that point in time where we are transitioning, the vast majority of patients will have already responded and hit kind of their maximal depth of response. You have a time to response of 1.4 months or six weeks, where we scan for the first time. So, more than half of our patients are already in response at their first scan, six weeks into therapy.

So, wanted to ensure that that profile was maintained. What we have seen in other datasets, particularly the 750 mg dataset, and I call that out because the every three-week dose is 2,250 every three weeks. That dose replicates the pharmacokinetic exposure profile of 750 weekly. What we know is, in looking at the 750 data, is our ability to maintain those responses once you capture a response. We actually saw similar levels of response between 750 and 1,500 mg. The key difference was the depth. So, we did, in data that we presented last year, we did a landmark at 24 weeks. What you saw at 24 weeks is you had a significant higher number of patients with a deep response at 24 weeks with 1,500 mg in comparison to 750. Again, that was why we did not start with 2,250 every three from the outset.

By doing it this way, we believe that we have been able to maintain the efficacy profile that we believe has the potential to be best in class. You have increased or improved on the administration schedule, which now synchronizes with KEYTRUDA at either every three or every six weeks. One of the less obvious things that we think we are going to be able to accomplish there is potentially to shift the tolerability profile. The reason we believe that is we looked at our 1,500 mg data. Some of the AEs that would be attributed to TGF-β, like anemia, like the mucosal bleeding that we have seen in some patients, you often see those in your best responders and late in the course of therapy.

Our perspective on why that is happening is because you have, at that point, you have significantly debulked the tumor, and you now have more TGF-β in the periphery because you do not have tumor for the molecule to bind to. So, by lowering the exposure at the 12-week mark, we actually think that there is an upside in tolerability, which gives us the ability to maximize the profile of the agent across efficacy, safety, as well as administration. The trial that we have conducted, which we initiated in the third quarter, starts patients at 12 weeks. At the 12-week mark, we are going to randomize those patients to either remaining on weekly therapy or transitioning to every three-week therapy. What we are looking for there is the proportion of patients that remain in response at a 24-week landmark.

Basically, the endpoint objective there is that you are not losing responses by transitioning people to a lower exposure and to a less frequent dose. It is not a pure non-inferiority with the line with the FDA. Basically, the way the endpoint is designed is the point estimate on the every three-week arm needs to sit within the confidence interval of the weekly, which allows us to do that trial with about 150 patients.

Stephen Willey
Senior Biotech Analyst, Stifel

Okay. There is another competitor molecule. Again, you spoke to the size of the market opportunity, right? Not surprising. J&J's amivantamab, they are pursuing phase III development in frontline, but with the addition of chemo on top of pembro and ami. We just saw that data presented at ESMO. Just any thoughts on what you saw there?

Ryan Cohlhepp
CEO, Bicara Therapeutics

Yeah. I think we had seen the top line response rate number in the high 70s, which I think, again, is a number you pay attention to in this class where even ourselves and Pito demonstrated in the mid-50% to low 60% range for response. I think what was a little surprising in that data. Yeah, and definitely as we have gotten feedback from KOLs, that stood out is a couple of things. What you consistently hear from treating physicians is they give chemotherapy because they want to debulk tumors fast and they want a rapid response. What we saw in that data with the triplet was a time to response that exceeded nine weeks. By comparison, our median time to response is six weeks.

You have now added chemotherapy, which is notorious for rapid responses, but you did not see any acceleration in time to response with that triplet regimen. The other thing, that the OrigAMI has multiple cohorts. Cohort two, I believe, is the cohort with pembro plus ami. If you look at that data from a PFS perspective to the cohort five, which is the triplet, PFS looks basically identical at around seven months. By comparison, we have showed with Ficera in an HPV-negative population, a PFS of 9.9 months. I think it is not clear what the added benefit of putting chemo into that regimen. Again, that is their pivotal trial that they are choosing to conduct. The one thing that is clear that you do get is a lot more tox.

What we saw in that dataset is, I think 26% of patients had to discontinue at least one study drug. You had more than 10% of patients who had a grade five event. I think what we saw in that dataset at ESMO this year was surprising on the efficacy side, with the lack of time to response and PFS, but what you would expect on the tox side.

One of the areas of feedback, I think people came out of that, and as we talked to physicians, I think their view on where they see utilizing a triplet regimen shifted and see less of a place for that regimen, compared to a ficera pembro regimen.

Stephen Willey
Senior Biotech Analyst, Stifel

Okay. I know J&J actually just secured an accelerated approval of ami in second-line patients. We've gotten this question a little bit, but do you see any impact of that drug now being available in the second line in the U.S. only? Is there any impact to FORTIFI, I guess, specifically with respect to this notion that a control arm patient in FORTIFI could progress and then subsequently receive ami as

Ryan Cohlhepp
CEO, Bicara Therapeutics

Yeah.

Stephen Willey
Senior Biotech Analyst, Stifel

a second-line therapy?

Ryan Cohlhepp
CEO, Bicara Therapeutics

Our view is that the risk is limited to very minimal. Part of that is the indication, what they were approved for, were in those patients who had progressed on chemotherapy plus PD-1.

Again, the two arms in the FORTIFI trial are ficera plus pembro and pembro monotherapy. I know potentially, you could get reimbursement or you could get use there if they had seen a pembro chemo regimen in the adjuvant setting, in the locally advanced setting. But we do believe that there is going to be limited second-line use of patients that would come off of the FORTIFI trial. I think the other thing that, as you think about, probably roughly 25%-30% of our phase III is going to be enrolled in the U.S. That actually was front-loaded. We started the trial there. As you think about, a lot of those patients who came on early in the trial, we initiated the trial in February of last year. A lot of those patients who would have come on early likely will have already progressed.

You are now seeing a disproportionate amount of our enrollment that sits outside of the U.S. Overall, our view on it is, again, very limited, to potentially no impact from a subsequent therapy confounding concern.

Stephen Willey
Senior Biotech Analyst, Stifel

Okay. Maybe we can spend the few minutes that we have left on colorectal. You have a couple of cohorts that you are looking at in the third-line setting or third-line plus setting.

Ryan Cohlhepp
CEO, Bicara Therapeutics

Yeah.

Stephen Willey
Senior Biotech Analyst, Stifel

I thought the commentary you made around perhaps maybe some of the early signals of safety and efficacy appear to be pretty constructive.

Ryan Cohlhepp
CEO, Bicara Therapeutics

Yeah.

Stephen Willey
Senior Biotech Analyst, Stifel

You can correct me if I am wrong, but just how are you now thinking about communicating this data to investors? I think you got it to something maybe early next year. What are the efficacy benchmarks that you kind of have in mind here?

Ryan Cohlhepp
CEO, Bicara Therapeutics

Yeah. On Monday at earnings, we said that we would be presenting that data in January. Since that call, we actually have received our acceptance at ASCO GI. We can now be clear in terms of where in January that is going to be presented. It will be presented at ASCO GI.

Stephen Willey
Senior Biotech Analyst, Stifel

Does that mean I have to go back to San Francisco after JP Morgan?

Ryan Cohlhepp
CEO, Bicara Therapeutics

I'm sure you can see it virtually.

Stephen Willey
Senior Biotech Analyst, Stifel

Okay.

Ryan Cohlhepp
CEO, Bicara Therapeutics

If not, we can talk about it.

Stephen Willey
Senior Biotech Analyst, Stifel

Okay.

Ryan Cohlhepp
CEO, Bicara Therapeutics

In terms of efficacy benchmarks, what we saw from the petosemtamab in a comparable dataset in the third-line plus setting was 10%. I think the other data that we find intriguing is Incyte's TGF-β PD-1, where you were able to see a slight increase off of that to 15% when they added Avastin to it. Again, they presented this data at ESMO. That response rate data went up into the high 20s, I think around 27%, 28%. As we look at it, we think that those are the relevant benchmarks, the 10%-15%. What's really important for us in that dataset is there some level of activity? We know the third-line setting is a very difficult population, but we've seen how a 10%-15% can translate into a 70%-80% in the front line and the second line setting.

I think our data from an efficacy perspective, it's less around how much data do you need to see there, unless the path is a registration approach in the third-line setting.

I think the other key element there is, what is the tolerability profile? Is the tolerability profile consistent with what we've seen in head and neck cancer? Because what we know as we move into earlier lines of CRC, it means you're going to do it in combination, either with chemotherapy or other novel mechanisms. I think some level of activity, but frankly, the more important element for us is, can we safely move this into the earlier lines in combination with other regimens and other drugs?

Stephen Willey
Senior Biotech Analyst, Stifel

Yeah, that Incyte data has kind of piqued my interest, not only just because of the response rates that you just referenced, but there's no falloff in patients with liver mets, right? Which is where you just wouldn't expect.

Ryan Cohlhepp
CEO, Bicara Therapeutics

Yeah. If you recall, we presented data in an anal canal cohort, I believe it was at AACR, where we showed in a number of our patients in that population who had liver metastases, resolution of those liver mets. We do think that as we play that forward and read it through into the colorectal population, do think that TGF-β mechanism will potentially have a differential effect in that population that has liver mets.

Stephen Willey
Senior Biotech Analyst, Stifel

Okay. Maybe you can just lastly speak to the balance sheet and just kind of what that allows you to execute on here going forward.

Ryan Cohlhepp
CEO, Bicara Therapeutics

We reported $442.3 million at the end of the quarter. What we have guided to is that takes us into early 2029 to fund enrollment of the FORTIFI trial through the survival endpoint, the FORTIFI-FLEX trial, some of our initial medical affairs and commercial build, as well as, I think, a little bit of signal-seeking work in other indications like colorectal cancer. We are, again, continuing to focus and execute on getting those patients enrolled in the FORTIFI trial and the FORTIFI-FLEX trial as quickly as possible, and look forward to our top-line data middle of next year.

Stephen Willey
Senior Biotech Analyst, Stifel

All right. Anything we didn't talk about that you want to quickly highlight before we wrap up?

Ryan Cohlhepp
CEO, Bicara Therapeutics

No, I think we've covered the bases.

Stephen Willey
Senior Biotech Analyst, Stifel

We did. All right. Thank you, Ryan. Thank you, everyone.

Ryan Cohlhepp
CEO, Bicara Therapeutics

Thanks a lot, Steve.